Abstract:Aim To further explore the association between Transmembrane 6 superfamily member 2 (TM6SF2) rs58542926 T/C gene polymorphism and hepatic fibrosis. Materials and Methods In this study the MEDLINE, PubMed, EMBASE, and CENTRAL databases were queried from inception to March 21, 2020. According to inclusion and exclusion criteria, case-control studies assessing the relationship between TM6SF2 rs58542926 T/C gene polymorphism and significant liver fibrosis were selected. NOS scale was used to evaluate the included literature. Stata 12.0 software was used for data analysis. Results In this meta-analysis,a total of 7 articles, including 2286 patients were included. Statistical analysis showed that the TM6SF2 gene polymorphism was associated with significant liver fibrosis in the allele contrast, recessive dominant models (T vs. C, OR=1.292, 95%CI 1.035-1.611, P=0.023; TT vs. CT+CC, OR=2.829, 95%CI 1.101-7.267, P=0.031). No significant publication bias was found after Egger’s test. Conclusion The present findings suggest that the TT genotype and T gene of TM6SF2 rs58542926 T/C gene polymorphism are associated with susceptibility to significant hepatic fibrosis. ### Competing Interest Statement The authors have declared no competing interest. ### Funding Statement There was no funding support. ### Author Declarations I confirm all relevant ethical guidelines have been followed, and any necessary IRB and/or ethics committee approvals have been obtained. Yes The details of the IRB/oversight body that provided approval or exemption for the research described are given below: There is nothing suitable All necessary patient/participant consent has been obtained and the appropriate institutional forms have been archived. Yes I understand that all clinical trials and any other prospective interventional studies must be registered with an ICMJE-approved registry, such as ClinicalTrials.gov. I confirm that any such study reported in the manuscript has been registered and the trial registration ID is provided (note: if posting a prospective study registered retrospectively, please provide a statement in the trial ID field explaining why the study was not registered in advance). Yes I have followed all appropriate research reporting guidelines and uploaded the relevant EQUATOR Network research reporting checklist(s) and other pertinent material as supplementary files, if applicable. Yes All the data mentioned in the manuscript are available. * TM6SF2 : transmembrane 6 superfamily member 2 HCC : hepatocellular carcinoma NAFLD : nonalcoholic fatty liver disease HCV : hepatitis C virus PSC : primary sclerosing cholangitis CHC : chronic hepatitis c CHB : chronic hepatitis b ALD : alcoholic fatty liver disease

The Genetics of Clinical Liver Diseases: Insight into the TM6SF2 E167K Variant

TM6SF2 E167K Variant, a Novel Genetic Susceptibility Variant, Contributing to Nonalcoholic Fatty Liver Disease

Relationship between transmembrane 6 superfamily member 2 E167K gene polymorphism and liver diseases

The Effect of the TM6SF2 E167K Variant on Liver Steatosis and Fibrosis in Patients with Chronic Hepatitis C: a Meta-Analysis.

Research progress on the relationship between TM6SF2 rs58542926 polymorphism and non-alcoholic fatty liver disease

ESR 2 polymorphism associated with the incidence and prognosis of hepatocellular carcinoma

Association of TM6SF2 rs58542926 gene polymorphism with the risk of non-alcoholic fatty liver disease and colorectal adenoma in Chinese Han population

Basic and translational evidence supporting the role of TM6SF2 in VLDL metabolism

TM6SF2 Rs58542926 is Related to Hepatic Steatosis, Fibrosis and Serum Lipids Both in Adults and Children: A Meta-Analysis

Transmembrane 6 Superfamily Member 2 Gene Variant Disentangles Nonalcoholic Steatohepatitis from Cardiovascular Disease

Association between TM6SF2 rs58542926 T/C Gene Polymorphism and Significant Liver Fibrosis:A Meta-analysis

Research progress of single-nucleotide polymorphism in theTM6SF2 rs58542926

TM6SF2 E167K Variant Overexpression Promotes Expression of Inflammatory Cytokines in the HCC Cell Line HEPA 1-6

Age Might Confound the Impact of the Transmembrane 6 Superfamily Member 2 E167k Polymorphism on Hepatic Fibrosis in Hepatitis C Virus-Infected Patients

The Additive Effects of the TM6SF2 E167K and PNPLA3 I148M Polymorphisms on Lipid Metabolism.

Association between TM6SF2 rs58542926 polymorphism and non-alcoholic fatty liver disease in Qingdao Han Population and molecular mechanism

The TNF-α Rs361525 and IFN-γ Rs2430561 Polymorphisms Are Associated with Liver Cirrhosis Risk: a Comprehensive Meta-Analysis

TM6SF2 E167K Variant Decreases PNPLA3-mediated PUFA Transfer to Promote Hepatic Steatosis and Injury in MASLD

TM6SF2-rs58542926 genotype has opposing effects on incidence of hepatic and cardiac events in a community cohort

Combining I148M and E167K Variants to Improve Risk Prediction for Nonalcoholic Fatty Liver Disease in Qingdao Han Population, China

E167K polymorphism of TM6SF2 gene affects cell cycle of hepatocellular carcinoma cell HEPA 1-6